C-Reactive Protein and Other Inflammatory Biomarkers as Predictors of Outcome Following Acute Coronary Syndromes

Seminars in Vascular Medicine

Volumn 3, Issue 4, 2003, Pages 375-383

  Abbate, Antonio ^a   Biondi Zoccai, Giuseppe G L ^a   Brugaletta, Salvatore ^a   Liuzzo, Giovanna ^a   Biasucci, Luigi M ^a  

^a CATHOLIC UNIVERSITY   (Italy)

Author keywords

Acute coronary syndromes; C reactive protein; Inflammation

Indexed keywords

BIOLOGICAL MARKER; C REACTIVE PROTEIN; TROPONIN;

ACUTE DISEASE; AGE; COMORBIDITY; HEART INFARCTION; HEART LEFT VENTRICLE PERFORMANCE; HEART MUSCLE ISCHEMIA; HEART MUSCLE NECROSIS; HIGH RISK PATIENT; HOSPITAL ADMISSION; HUMAN; INFLAMMATION; MEDICAL DOCUMENTATION; NORMAL VALUE; PREDICTION; PROGNOSIS; REVIEW; RISK ASSESSMENT;

ANGINA, UNSTABLE; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; HUMANS; INFLAMMATION; MYOCARDIAL INFARCTION; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RECURRENCE; RISK ASSESSMENT; SYNDROME; TROPONIN;

EID: 1642494588     PISSN: 15289648     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2004-815695     Document Type: Review

References (68)

1. Wallentin L, Lagerqvist B, Husted S, et al, for the FRISC II investigators. Outcome at 1 year after an invasive compared with a non-invasive strategy in unstable coronary-artery disease: the FRISC II invasive randomised trial. Lancet 2000; 356:9-16
2. Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) Study Investigators. Inhibition of the platelet IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. N Engl J Med 1998; 338:1488-1497
3. Hamm CW, Braunwald E. A classification of unstable angina revisited. Circulation 2000;102:118-122
4. Patel DJ, Gomma AH, Knight CJ, et al. Why is recurrent myocardial ischaemia a predictor of adverse outcome in unstable angina? Eur Heart J 2001;22:1991-1996
5. Dangas G, Mehran R, Wallenstein S, et al. Correlation of angiographic morphology and clinical presentation in unstable angina. J Am Coll Cardiol 1997;29:519-525
6. Vetrovec GW, Cowley MJ, Overton H, Richardson DW. Intracoronary thrombus in syndromes of unstable myocardial ischemia. Am Heart J 1981;102:1202-1208
7. Heeschen C, van Den Brand MJ, Hamm CW, Simoons ML. Angiographic findings in patients with refractory unstable angina according to troponin T status. Circulation 1999;100: 1509-1514
8. Hamm CW, Heeschen C, Goldmann B, et al. Benefit of abciximab in patients with refractory unstable angina in relation to serum troponin T levels. N Engl J Med 1999;340:1623-1629
9. Lenderink T, Boersma E, Heeschen C, et al. Elevated troponin T and C-reactive protein predict impaired outcome for 4 years in patients with refractory unstable angina, and troponin T predicts benefit of treatment with abciximab in combination with PTCA. Eur Heart J 2003;24:77-85
10. van der Wal AC, Becker AE, van der Loos CM, Das PK. Site of intimal rupture or erosion of thrombosed coronary atherosclerotic plaques is characterized by an inflammatory process irrespective of the dominant plaque morphology. Circulation 1994;89:36-44
11. Arbustini E, Grasso M, Diegoli M, et al. Coronary atherosclerotic plaques with and without thrombus in ischemic heart syndromes: a morphologic, immunohistochemical, and biochemical study. Am J Cardiol 1991;68(suppl):36B-50B
12. DiSciascio G, Cowley MJ, Goudreau E, Vetrovec GW, Johnson DE. Histopathologic correlates of unstable ischemic syndromes in patients undergoing directional coronary atherectomy: in vivo evidence of thrombosis, ulceration, and inflammation. Am Heart J 1994;128:419-426
13. Buffon A, Biasucci LM, Liuzzo G, D'Onofrio G, Crea F, Maseri A. Widespread coronary inflammation in unstable angina. N Engl J Med 2002;347:5-12
14. Biasucci LM, Liuzzo G, Colizzi C, Rizzello V. Clinical use of C-reactive protein for the prognostic stratification of patients with ischemic heart disease. Ital Heart J 2001;12:164-171
15. Liuzzo G, Biasucci LM, Gallimore JR, et al. The prognostic value of C-reactive protein and serum amyloid A protein in severe unstable angina. N Engl J Med 1994;331:417-424
16. Ferreiros ER, Boissonnet CP, Pizarro R, et al. Independent prognostic value of C-reactive protein in unstable angina. Circulation 1999;100:1958-1963
17. Oltrona L, Ardissino D, Merlini PA, et al. C-reactive protein elevation and early outcome in patients with unstable angina pectoris. Am J Cardiol 1997;80:1002-1006
18. Morrow DA, Rifai N, Altman EM, et al. C-reactive protein is a potent predictor of mortality independently of and in combination with troponin T in acute coronary syndromes: a TIMI 11A substudy. Thrombolysis In Myocardial Infarction 11A. J Am Coll Cardiol 1998;31:1460-1465
19. Benamer H, Steg PG, Benessiano J, et al. Comparison of the prognostic value of C-reactive protein and troponin I in patients with unstable angina pectoris. Am J Cardiol 1998;82:845-850
20. Biasucci LM, Meo A, Buffon A, et al. Independent prognostic value of C-reactive protein levels for in-hospital death and myocardial infarction in unstable angina. Circulation 2000; 102(suppl II):140
21. Verheggen PWHM, de Maat MPM, Manger Cats V, et al. Inflammatory status as a main determinant of outcome in patients with unstable angina, independent of coagulation activation and endothelial cell function. Eur Heart J 1999;20:567-574
22. Mueller C, Buettner HJ, Hodgson JM, et al. Inflammation and long-term mortality after non-ST elevation acute coronary syndrome treated with a very early invasive strategy in 1042 consecutive patients. Circulation 2002;105:1412-1415
23. Biasucci LM, Liuzzo G, Grillo RL, et al. Elevated levels of C-reactive protein at discharge in patients with unstable angina predict recurrent instability. Circulation 1999;99:855-860
24. Toss H, Lindhal B, Siegbahn A, Wallentin L, for the FRISC Study Group. Prognostic influence of increased fibrinogen and C-reactive protein levels in unstable coronary artery disease. Circulation 1997;96:4204-4210
25. Lindhal B, Toss H, Siegbahn A, et al, for the FRISC Study Group. Markers of myocardial damage and inflammation in relation to long-term mortality in unstable coronary artery disease. N Engl J Med 2000;343:1139-1147
26. Cannon CP, Weintraub WS, Demopoulos L, et al. High-sensitivity C-reactive protein (hs-CRP) to predict 6 month mortality and relative benefit of invasive vs. conservative strategy in patients with unstable angina: primary results of the TACTICS-TIMI 18 C-reactive protein substudy. J Am Coll Cardiol 2001;37(suppl A):315A
27. Bazzino O, Ferreiros ER, Pizarro R, Corrado G. C-reactive protein and the stress tests for risk stratification of patients recovering from unstable angina pectoris. Am J Cardiol 2001; 87:1235-1239
28. Koukkenen H, Penttilä K, Kemppainen A, et al. C-reactive protein, fibrinogen, interleukin-6 and tumor necrosis factor-α in the prognostic classification of unstable angina pectoris. Ann Med 2001;33:37-47
29. Rebuzzi A, Quaranta C, Liuzzo G, et al. Incremental prognostic value of serum levels of troponin T and C-reactive protein on admission in patients with unstable angina pectoris. Am J Cardiol 1998;82:715-719
30. Haverkate F, Thompson SG, Pyke SD, Gallimore JR, Pepys MB. Production of C-reactive protein and risk of coronary events in stable and unstable angina. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. Lancet 1997;349:462-466
31. Heeschen C, Hamm CW, Bruemmer J, et al, for the CAPTURE Investigators. Predictive value of C-reactive protein and troponin T in patients with unstable angina: a comparative analysis. J Am Coll Cardiol 2000;35:1535-1542
32. Buffon A, Liuzzo G, Biasucci LM, et al. Preprocedural serum levels of C-reactive protein predict early complications and late restenosis after coronary angioplasty. J Am Coll Cardiol 1999;34:1512-1521
33. Chew DP, Bhatt DL, Robbins MA, et al. Incremental prognostic value of elevated baseline C-reactive protein among established markers of risk in percutaneous coronary intervention. Circulation 2001;104:992-997
34. Versaci F, Gaspardone A, Tomai F, et al. Predictive value of C-reactive protein in patients with unstable angina pectoris undergoing coronary artery stent implantation. Am J Cardiol 2000;85:92-95
35. Walter DH, Fichtlscherer S, Sellwig M, et al. Preprocedural C-reactive protein levels and cardiovascular events after coronary stent implantation. J Am Coll Cardiol 2001;37:839-846
36. de Winter RJ, Heyde GS, Koch KT, et al. The prognostic value of pre-procedural plasma C-reactive protein in patients undergoing elective coronary angioplasty. Eur Heart J 2002; 23:960-966
37. Ellis SG, Chew D, Chan A, Whitlow PL, Schneider JP, Topol EJ. Death following creatine kinase-MB elevation after coronary intervention. Circulation 2002;106:1205-1210
38. Versaci F, Gaspardone A, Tomai F, et al. Immunosuppressive Therapy for the Prevention of Restenosis after Coronary Artery Stent Implantation (IMPRESS Study). J Am Coll Cardiol 2002;40:1935-1942
39. de Lemos JA, Morrow DA, Bentley JH, et al. The prognostic value of B-type natriuretic peptide in patients with acute coronary syndromes. N Engl J Med 2001;345:1014-1021.
40. de Lemos JA, Morrow DA, Bentley JH, et al. The prognostic value of B-type natriuretic peptide and acute coronary syndromes. N Engl J Med 2001;345(14):1014-1021
41. Sabatine MS, Morrow DA, de Lemos JA, et al. Multimarker approach to risk stratification in non-ST elevation acute coronary syndromes. Simultaneous assessment of troponin I, C-reactive protein, and B-type natriuretic peptide. Circulation 2002;105:1760-1763
42. Zebrack JS, Muhlestein JB, Horne BD, Anderson JL, for the Intermountain Heart Collaboration Study Group. C-reactive protein and angiographic coronary artery disease: independent and additive predictors of risk in subjects with angina. J Am Coll Cardiol 2002;39:632-637
43. Gabay C, Kushner I. Acute phase proteins and other systemic responses to inflammation. N Engl J Med 1999;340:448-454
44. Biasucci LM, Vitelli A, Liuzzo G, et al. Elevated levels of interleukin-6 in unstable angina. Circulation 1996;94:874-877
45. Biasucci LM, Liuzzo G, Fantuzzi G, et al. Increasing levels of interleukin (IL)-iRa and IL-6 during the first 2 days of hospitalization in unstable angina are associated with increased risk of in-hospital coronary events. Circulation 1999;99: 2079-2084
46. Koukkunen H, Penttilä K, Kemppainen A, et al. C-reactive protein, fibrinogen, interleukin-6 and tumor necrosis factor-α in the prognostic classification of unstable angina pectoris. Ann Med 2001;33:37-47
47. Liuzzo G, Kopecky SL, Frye RL, et al. Perturbation of the T-cell repertoire in patients with unstable angina. Circulation 1999;100:2135-2139
48. Thompson SG, Kienast J, Pyke SD, et al. Hemostatic factors and of myocardial infarction or sudden death in patients with angina pectoris. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. N Engl J Med 1995;332:635-641
49. Wallen NH, Held C, Rehnqvist N, Hjemdhal P. Elevated serum intercellular adhesion molecule-1 and vascular adhesion molecule-1 among patients with stable angina pectoris who suffer cardiovascular death or non-fatal myocardial infarction. Eur Heart J 1999;20:1039-1043
50. Mulvihill NT, Foley JB, Murphy RT, Curtin R, Crean PA, Walsh M. Risk stratification in unstable angina and non-Q wave myocardial infarction using soluble cell adhesion molecules. Heart 2001;85:623-627
51. Ridker PM, Rifai N, Pfeffer M, et al. Elevation of tumor necrosis factor-alpha and increased risk of recurrent coronary events after myocardial infarction. Circulation 2000;101:2149-2153
52. Abbate A, Vecile E, Fiotti N, et al. Plasma concentrations of interleukin-2 soluble receptor in mild ischaemic left ventricular dysfunction. Eur J Heart Fail 2003;5:23-25
53. Patti C, Di Sciascio G, D'Ambrosio A, Dicuonzo G, Abbate A, Dobrina A. Prognostic value of interleukin-1 receptor antagonist in patients undergoing percutaneous coronary intervention. Am J Cardiol 2002;89:372-376
54. Blankenberg S, Tiret L, Bickel C, et al. Interleukin-18 is a strong predictor of cardiovascular death in stable and unstable angina. Circulation 2002;105:143-149
55. Biasucci LM, Santamaria M, Angiolillo DJ, et al. Interleukin-18 levels suggest different inflammatory pathways in unstable angina-18. J Am Coll Cardiol 2003;41(6 Suppl B):363
56. Ridker PM, Rifai N, Clearfield M, et al, for the Air Force/ Texas Coronary Atherosclerosis Prevention Study Investigators. Measurement of C-reactive protein for targeting of statin therapy in the primary prevention of acute coronary events. N Engl J Med 2001;344:1959-1965
57. Kennon S, Price CP, Mills PG, et al. The effect of aspirin on C-reactive protein as a marker of risk in unstable angina. J Am Coll Cardiol 2001;37:1266-1270
58. Chew DP, Bhatt DL, Robbins MA, et al. Effect of clopidogrel added to aspirin before percutaneous coronary intervention on the risk associated with C-reactive protein. Am J Cardiol 2001;88:672-674
59. Buffon A, Liuzzo G, Angiolillo DJ, et al. Abciximab decreases cytokine production by circulating monocytes in patients with unstable angina and elevated inflammatory markers. J Am Coll Cardiol 2001;37(suppl A):818A
60. Lincoff AM, Kereiakes DJ, Mascelli MA, et al. Abciximab depresses the rise in levels of circulating inflammatory markers after percutaneous coronary revascularization. Circulation 2001;104:163-167
61. Jialal I, Stein D, Balis D, et al. Effect of hydroxymethyl glutaryl coenzyme A reductase inhibitor therapy on high sensitive C-reactive protein levels. Circulation 2001;103:1933-1935
62. Ottenvanger JP, Armstrong P, Barnathan ES, et al. Long-term results after the glycoprotein IIb/IIIa inhibitor abciximab in unstable angina. Circulation 2003;107:437-442
63. Albert MA, Glynn RJ, Ridker PM. Alcohol consumption and plasma concentration of C-reactive protein. Circulation 2003; 107:443-447
64. Bhatt DL, Topol EJ. Need to test the arterial inflammation hypothesis. Circulation 2002;106:136-140
65. Pearson TA, Mensah GA, Alexander RW, et al. Markers of inflammation and cardiovascular disease. Application to clinical and public health practice. Circulation 2003;107:499-511
66. Bertrand ME, Simoons ML, Fox KAA, et al. Management of acute coronary syndromes without persistent ST segment elevation. Recommendations of the Task Force of the European Society of Cardiology. Eur Heart J 2000;21:1406-1432
67. Horne BD, Muhlestein JB, Carlquist JF, et al. Statin therapy, lipid levels, C-reactive protein and the survival of patients with angiographically severe coronary artery disease. J Am Coll Cardiol 2000;36:1774-1780
68. Zebrack JS, Anderson JL, Maycock CA, et al. Usefulness of high-sensitivity C-reactive protein in predicting long-term risk of death or acute myocardial infarction in patients with unstable or stable angina pectoris or acute myocardial infarction. Am J Cardiol 2002;89:145-149